These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15482004)

  • 1. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
    Frampton JE; Easthope SE
    Drugs; 2004; 64(21):2475-92. PubMed ID: 15482004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on gefitinib in non-small-cell lung cancer.
    Frampton JE; Easthope SE
    Am J Pharmacogenomics; 2005; 5(2):133-6. PubMed ID: 15813676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib for advanced or metastatic non-small cell lung cancer.
    Perras C
    Issues Emerg Health Technol; 2004 Apr; (55):1-4. PubMed ID: 15085875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
    JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
    Cersosimo RJ
    Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib: current status in the treatment of non-small cell lung cancer.
    Tanović A; Alfaro V
    Drugs Today (Barc); 2004 Oct; 40(10):809-27. PubMed ID: 15605116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib.
    Culy CR; Faulds D
    Drugs; 2002; 62(15):2237-48; discussion 2249-50. PubMed ID: 12381224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
    Forsythe B; Faulkner K
    Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib therapy for advanced non-small-cell lung cancer.
    Liu CY; Seen S
    Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.